Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:684
Name hepatocellular carcinoma
Definition A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver.
Source DiseaseOntology.org
Alt Ids DOID:5005
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer liver carcinoma hepatocellular carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown FH535 hepatocellular carcinoma not applicable detail...
Unknown unknown Fluorouracil + Interferon alpha-2b hepatocellular carcinoma not applicable detail...
Unknown unknown Linifanib hepatocellular carcinoma not applicable detail...
Unknown unknown Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Torin 2 hepatocellular carcinoma not applicable detail...
CTNNB1 mutant PMED-1 hepatocellular carcinoma sensitive detail...
Unknown unknown LCL161 + Paclitaxel hepatocellular carcinoma not applicable detail...
Unknown unknown Fingolimod + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown PI-88 hepatocellular carcinoma not applicable detail...
Unknown unknown Lenvatinib hepatocellular carcinoma not applicable detail...
Unknown unknown NanoHHI hepatocellular carcinoma not applicable detail...
Unknown unknown OPB-31121 hepatocellular carcinoma no benefit detail...
Unknown unknown YW3-56 hepatocellular carcinoma not applicable detail...
Unknown unknown Ascrinvacumab hepatocellular carcinoma not applicable detail...
Unknown unknown NSC156529 hepatocellular carcinoma not applicable detail...
Unknown unknown 17-Demethoxy-reblastatin hepatocellular carcinoma not applicable detail...
Unknown unknown Refametinib + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Resminostat + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Domatinostat hepatocellular carcinoma not applicable detail...
Unknown unknown Lenalidomide + Sorafenib hepatocellular carcinoma no benefit detail...
Unknown unknown Codrituzumab hepatocellular carcinoma no benefit detail...
Unknown unknown Brivanib hepatocellular carcinoma no benefit detail...
Unknown unknown Ramucirumab hepatocellular carcinoma not applicable detail...
Unknown unknown Selumetinib + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Erlotinib + Sorafenib hepatocellular carcinoma no benefit detail...
TP53 Y220C CP-31398 hepatocellular carcinoma sensitive detail...
TP53 R249S CP-31398 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos AZD4547 hepatocellular carcinoma sensitive detail...
FGFR1 pos FGFR2 pos PHA-665752 hepatocellular carcinoma no benefit detail...
Unknown unknown SF1126 hepatocellular carcinoma not applicable detail...
Unknown unknown SF1126 + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Metformin + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Cabozantinib + CT-707 hepatocellular carcinoma not applicable detail...
Unknown unknown CT-707 + PHA-665752 hepatocellular carcinoma not applicable detail...
Unknown unknown Regorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Droxinostat hepatocellular carcinoma not applicable detail...
Unknown unknown Chiauranib hepatocellular carcinoma not applicable detail...
Unknown unknown PEGPH20 hepatocellular carcinoma not applicable detail...
Unknown unknown Riluzole hepatocellular carcinoma not applicable detail...
Unknown unknown Foretinib hepatocellular carcinoma not applicable detail...
Unknown unknown RU-A1 hepatocellular carcinoma not applicable detail...
Unknown unknown Fluorouracil + RU-A1 hepatocellular carcinoma not applicable detail...
Unknown unknown Nivolumab hepatocellular carcinoma not applicable detail...
Unknown unknown CEBPA-51 hepatocellular carcinoma not applicable detail...
Unknown unknown SGI-1027 hepatocellular carcinoma not applicable detail...
Unknown unknown KU-0063794 hepatocellular carcinoma not applicable detail...
Unknown unknown Camrelizumab hepatocellular carcinoma not applicable detail...
Unknown unknown GNS561 hepatocellular carcinoma not applicable detail...
Unknown unknown Bevacizumab + MINT1526A hepatocellular carcinoma not applicable detail...
NRAS mutant Refametinib + Sorafenib hepatocellular carcinoma sensitive detail...
Unknown unknown Pembrolizumab hepatocellular carcinoma not applicable detail...
Unknown unknown Cabozantinib hepatocellular carcinoma not applicable detail...
Unknown unknown Camrelizumab + Rivoceranib hepatocellular carcinoma not applicable detail...
PIK3CA mutant Sorafenib hepatocellular carcinoma decreased response detail...
PTEN mutant Sorafenib hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified PD-L1 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody hepatocellular carcinoma decreased response detail...
CTNNB1 act mut unspecified CTLA4 antibody + unspecified PD-1 antibody hepatocellular carcinoma decreased response detail...
Unknown unknown Orlistat hepatocellular carcinoma not applicable detail...
Unknown unknown Orlistat + Paclitaxel hepatocellular carcinoma not applicable detail...
Unknown unknown Dalantercept + Sorafenib hepatocellular carcinoma no benefit detail...
Unknown unknown Mogamulizumab + Nivolumab hepatocellular carcinoma not applicable detail...
TP53 Y220C SLMP53-2 hepatocellular carcinoma sensitive detail...
TP53 Y220C SLMP53-2 + Sorafenib hepatocellular carcinoma sensitive detail...
ATRX del Adavosertib hepatocellular carcinoma sensitive detail...
Unknown unknown Ipilimumab + Nivolumab hepatocellular carcinoma not applicable detail...
Unknown unknown Novaferon hepatocellular carcinoma not applicable detail...
Unknown unknown DRP-104 + unspecified PD-L1 antibody hepatocellular carcinoma not applicable detail...
Unknown unknown DRP-104 hepatocellular carcinoma not applicable detail...
Unknown unknown Atezolizumab + Bevacizumab hepatocellular carcinoma not applicable detail...
FLT3 over exp Sorafenib hepatocellular carcinoma sensitive detail...
Unknown unknown Mipsagargin hepatocellular carcinoma not applicable detail...
Unknown unknown Intuvax hepatocellular carcinoma not applicable detail...
Unknown unknown Intuvax + Sorafenib hepatocellular carcinoma not applicable detail...
Unknown unknown Avelumab hepatocellular carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00986661 Phase I PV-10 A Study to Assess PV-10 Chemoablation of Cancer of the Liver Recruiting USA 0
NCT01015833 Phase III Doxorubicin Sorafenib Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Active, not recruiting USA | CAN 1
NCT01075113 Phase I Sorafenib + Vorinostat Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT01141478 Phase I Sorafenib Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria Unknown status USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Suspended USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA 3
NCT01246986 Phase II Galunisertib + Sorafenib Galunisertib A Study of LY2157299 in Participants With Hepatocellular Carcinoma Completed USA 6
NCT01306058 Phase Ib/II Carotuximab + Sorafenib Sorafenib and TRC105 in Hepatocellular Cancer Completed USA 0
NCT01356628 Phase II Palbociclib A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer Active, not recruiting USA 0
NCT01421524 Phase I CC-122 Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Active, not recruiting USA 4
NCT01556490 Phase III Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer Active, not recruiting USA | CAN 9
NCT01567930 Phase II Temsirolimus Temsirolimus as Second-line Therapy in HCC Unknown status USA 0
NCT01624285 Phase II Sorafenib Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer Active, not recruiting USA 0
NCT01628640 Phase I VSV-IFN-beta Viral Therapy in Treating Patient With Liver Cancer Active, not recruiting USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Active, not recruiting USA 0
NCT01655693 Phase III Doxorubicin Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) Completed USA 10
NCT01658878 Phase I Nivolumab Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) Active, not recruiting USA | CAN 11
NCT01666756 Phase I Sorafenib + YIV-906 Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Completed USA 0
NCT01687673 Phase II Sorafenib + Temsirolimus Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Completed USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA 5
NCT01730937 Phase III Sorafenib Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Active, not recruiting USA | CAN 3
NCT01754987 Phase Ib/II Sorafenib A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective Completed USA 0
NCT01755767 Phase III Tivantinib Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Completed USA | CAN 14
NCT01761266 Phase III Lenvatinib Sorafenib A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma Active, not recruiting USA | CAN 19
NCT01774344 Phase III Regorafenib Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE) Completed USA 20
NCT01775501 Phase II Sorafenib Fluorouracil Oxaliplatin Leucovorin Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed USA 0
NCT01801163 Phase I Sorafenib A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) Withdrawn USA 0
NCT01835223 Phase Ib/II Tivozanib Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT01840592 Phase II Doxorubicin + Sorafenib Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib Active, not recruiting USA 0
NCT01849588 FDA approved Sorafenib Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Terminated USA 0
NCT01853618 Phase I Tremelimumab Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed USA 0
NCT01887717 Phase III Sorafenib Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein Terminated USA 5
NCT01900002 Phase II Sorafenib Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) Completed USA 0
NCT01908426 Phase III Cabozantinib Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Completed USA | CAN 17
NCT01915602 Phase II Refametinib + Sorafenib Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) Completed USA 20
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA 2
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting USA | CAN 13
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT02024087 Phase Ib/II Dalantercept + Sorafenib Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02069145 Phase I Ipafricept + Sorafenib Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Completed USA 0
NCT02072486 Phase I Sorafenib Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed USA 0
NCT02101593 Phase I ADI-PEG 20 Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer Completed USA 0
NCT02128958 Phase II CF102 Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Active, not recruiting USA 4
NCT02143401 Phase I Navitoclax + Sorafenib Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Active, not recruiting USA 0
NCT02151864 Phase I Sonidegib LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis Completed USA 0
NCT02174549 Phase I Tirapazamine Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Active, not recruiting USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02227914 Phase Ib/II Oprozomib Sorafenib Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Withdrawn USA 0
NCT02232633 Phase II BBI503 A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Completed CAN 0
NCT02279719 Phase Ib/II Sorafenib BBI503 + Sorafenib Napabucasin + Sorafenib A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Completed USA 0
NCT02288507 Phase I Sorafenib Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Withdrawn USA 0
NCT02292173 Phase I Sorafenib + Trametinib Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer Active, not recruiting USA 0
NCT02314052 Phase Ib/II DCR-MYC Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma Terminated USA 2
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA 3
NCT02323906 Phase Ib/II CC-122 + Sorafenib Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer Terminated USA 0
NCT02406508 Phase II Melphalan Sorafenib Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Withdrawn USA 0
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA 1
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02435433 Phase III Ramucirumab A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) Recruiting USA | CAN 18
NCT02460991 Phase I Sorafenib Doxorubicin A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma Terminated USA 0
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Active, not recruiting USA 11
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting USA 8
NCT02519348 Phase II Tremelimumab Durvalumab A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma Active, not recruiting USA 8
NCT02524119 Phase II Ribociclib LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) Terminated USA 0
NCT02528643 Phase II Enzalutamide A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma Completed USA | CAN 7
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA 1
NCT02560779 Phase Ib/II Carotuximab + Sorafenib Trial of TRC105 and Sorafenib in Patients With HCC Completed USA 0
NCT02562755 Phase III JX-594 Sorafenib Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed USA | CAN 14
NCT02564614 Phase I EZN-2968 A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) Completed USA 0
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Completed USA 7
NCT02575339 Phase Ib/II Sorafenib Sapanisertib MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Active, not recruiting USA 0
NCT02576509 Phase III Nivolumab Sorafenib A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA | CAN 20
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting USA 0
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Completed USA 3
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02642913 Phase Ib/II Enzalutamide Sorafenib Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Completed USA 0
NCT02658019 Phase II Pembrolizumab Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Completed USA 0
NCT02675946 Phase I CGX1321 Study of CGX1321 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT02702401 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) Active, not recruiting 0
NCT02702414 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) Active, not recruiting 0
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Active, not recruiting USA 6
NCT02795429 Phase Ib/II Spartalizumab Capmatinib + Spartalizumab Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Active, not recruiting CAN 7
NCT02821754 Phase Ib/II Durvalumab + Tremelimumab A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Recruiting USA 0
NCT02834780 Phase I H3B-6527 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Active, not recruiting USA | CAN 9
NCT02837029 Phase I Nivolumab Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer Active, not recruiting USA 0
NCT02842125 Phase I Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Terminated USA 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting 1
NCT02859324 Phase Ib/II CC-122 + Nivolumab A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) Completed USA 3
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02905188 Phase I GLYCAR T cells Cyclophosphamide + Fludarabine Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (GLYCAR) Recruiting USA 0
NCT02906397 Phase I Galunisertib A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting USA 0
NCT02939807 Phase II ABC294640 A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma Withdrawn USA 0
NCT02940496 Phase Ib/II Pembrolizumab Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Active, not recruiting USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting USA | CAN 7
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02988440 Phase I Sorafenib + Spartalizumab Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients Completed USA | CAN 6
NCT02989870 Phase I Bavituximab + Sorafenib Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Withdrawn USA 0
NCT03006926 Phase I Lenvatinib + Pembrolizumab A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma Active, not recruiting USA 6
NCT03037437 Phase II Hydroxychloroquine + Sorafenib Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Recruiting USA 0
NCT03059147 Phase I SF1126 A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting USA 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting USA 0
NCT03099564 Phase I Pembrolizumab Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Recruiting USA 0
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Recruiting USA 3
NCT03138889 Phase I NKTR-214 + Pembrolizumab A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL) Recruiting USA 5
NCT03143270 Phase I Nivolumab A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Recruiting USA 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA 1
NCT03145558 Phase II Doxorubicin Tirapazamine TATE Versus TACE in Intermediate Stage HCC (TATE) Active, not recruiting USA 0
NCT03203304 Phase I Nivolumab Ipilimumab + Nivolumab Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma Active, not recruiting USA 0
NCT03211416 Phase Ib/II Pembrolizumab + Sorafenib Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer Recruiting USA 0
NCT03222076 Phase II Ipilimumab + Nivolumab Nivolumab Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Active, not recruiting USA 0
NCT03253289 Phase I Meclizine Meclizine for Hepatocellular Carcinoma (OPTIM) Suspended USA 0
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting USA 0
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Recruiting USA | CAN 15
NCT03299946 Phase I Cabozantinib + Nivolumab Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) Active, not recruiting USA 0
NCT03316222 Phase Ib/II GNS561 Study of GNS561 in Patients With Liver Cancer Recruiting USA 2
NCT03316872 Phase II Pembrolizumab Study of Pembrolizumab and Radiotherapy in Liver Cancer Recruiting CAN 0
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated USA 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03347292 Phase I Pembrolizumab + Regorafenib Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC Active, not recruiting USA 1
NCT03382886 Phase I Bevacizumab + Nivolumab Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE) Terminated USA 0
NCT03383458 Phase III Nivolumab A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation Active, not recruiting USA | CAN 24
NCT03412773 Phase III Tislelizumab Sorafenib Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC Active, not recruiting USA 10
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Recruiting USA 0
NCT03419897 Phase II Tislelizumab Study of BGB-A317 in Patients With Previously Treated Unresectable HCC Active, not recruiting 8
NCT03433703 Phase II Lenvatinib Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) Terminated USA 0
NCT03434379 Phase III Atezolizumab + Bevacizumab Sorafenib A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] Active, not recruiting USA | CAN 15
NCT03439891 Phase II Nivolumab + Sorafenib Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Active, not recruiting USA 0
NCT03441100 Phase I Cyclophosphamide + Fludarabine Aldesleukin IMA202 TCR-engineered T Cells in NSCLC and HCC Patients Recruiting USA 1
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting 1
NCT03482102 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Recruiting USA 0
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Terminated USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting USA 0
NCT03519997 Phase II Bavituximab + Pembrolizumab A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting USA 0
NCT03533582 Phase II Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting USA | CAN 4
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Recruiting USA 0
NCT03563170 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib Sorafenib QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Withdrawn USA 0
NCT03582618 Phase II CVM-1118 + Sorafenib CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma Recruiting USA 1
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Active, not recruiting USA | CAN 8
NCT03638141 Phase II Durvalumab + Tremelimumab CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Recruiting USA 0
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting USA 0
NCT03655002 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer Recruiting USA 0
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting USA 10
NCT03665129 Phase I Durvalumab + IPH5401 IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Active, not recruiting USA 1
NCT03680508 Phase II Dostarlimab-gxly + TSR-022 TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer Recruiting USA 0
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Active, not recruiting USA 5
NCT03695250 Phase Ib/II BMS-986205 + Nivolumab BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer Recruiting USA 0
NCT03713593 Phase III Lenvatinib Lenvatinib + Pembrolizumab Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Active, not recruiting USA | CAN 19
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA 5
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting USA 0
NCT03755791 Phase III Cabozantinib Sorafenib Atezolizumab + Cabozantinib Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) Recruiting USA | CAN 32
NCT03778957 Phase III Durvalumab Bevacizumab + Durvalumab A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) Recruiting USA | CAN 16
NCT03781960 Phase II Abemaciclib + Nivolumab Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma Active, not recruiting USA 0
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Recruiting USA 0
NCT03812562 Phase I Nivolumab Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection Active, not recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA 0
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | CAN 9
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting USA 3
NCT03836352 Phase II DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Recruiting USA | CAN 0
NCT03847428 Phase III Durvalumab Bevacizumab + Durvalumab Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) Recruiting USA | CAN 22
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting USA 0
NCT03867084 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) Recruiting USA | CAN 28
NCT03897543 Phase Ib/II ABX196 + Nivolumab ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Recruiting USA 0
NCT03908840 Phase I TBI-302 Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma Unknown status USA 0
NCT03916627 Phase II Cemiplimab Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC Recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting USA 4
NCT03937830 Phase II Bevacizumab + Doxorubicin + Durvalumab Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma Recruiting USA 0
NCT03964233 Phase I BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 BI 907828 A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA 1
NCT03970616 Phase Ib/II Durvalumab + Tivozanib A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma Recruiting USA 0
NCT03993873 Phase I TPX-0022 Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET Recruiting USA 3
NCT03998033 Phase Ib/II ET140202 Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma Terminated USA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Recruiting USA 0
NCT04039607 Phase III Lenvatinib Sorafenib Ipilimumab + Nivolumab A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) Recruiting USA | CAN 24
NCT04050462 Phase II BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients Recruiting USA 0
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Recruiting USA 4
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04102098 Phase III Atezolizumab + Bevacizumab A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) Recruiting USA | CAN 24
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Recruiting USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04123379 Phase II BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Active, not recruiting USA 0
NCT04134559 Phase II Pembrolizumab Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma Recruiting USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA 0
NCT04158700 Phase Ib/II LY3200882 + Pembrolizumab A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Withdrawn USA 2
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Suspended USA 0
NCT04204850 Phase II Cabozantinib Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx) Recruiting CAN 0
NCT04246177 Phase III Lenvatinib + Pembrolizumab Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Recruiting USA 23
NCT04246671 Phase Ib/II TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients Recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04291105 Phase II Cemiplimab + VSV-hIFNbeta-NIS Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Recruiting USA 0
NCT04311710 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) Recruiting USA 8
NCT04327700 Phase II Regorafenib Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib Recruiting USA 0
NCT04340193 Phase III Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) Recruiting USA | CAN 20
NCT04374877 Phase I SRF388 Study of SRF388 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04423029 Phase Ib/II DF6002 + Pembrolizumab DF6002 Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04430452 Phase II Durvalumab Durvalumab + Tremelimumab Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition Not yet recruiting USA 0
NCT04442581 Phase II Cabozantinib + Pembrolizumab Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer Recruiting USA 0
NCT04472767 Phase II Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma Recruiting USA 0
NCT04476329 Phase II Regorafenib Optimization for Regorafenib in HCC (ReDos HCC) Recruiting USA 0
NCT04497038 Phase Ib/II Cabozantinib Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy Recruiting USA 0
NCT04502082 Phase Ib/II ET140203 Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET121) Recruiting USA 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Recruiting USA 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Recruiting USA | CAN 9
NCT04524871 Phase Ib/II Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + MTIG7192A Atezolizumab + Bevacizumab A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) Recruiting USA 6
NCT04541173 Phase II Atezolizumab + Bevacizumab Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04563338 Phase II Atezolizumab Atezolizumab + Bevacizumab Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases Not yet recruiting CAN 0
NCT04605731 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Suspended USA 0
NCT04634357 Phase Ib/II ET140203 ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) Not yet recruiting USA 0
NCT04658147 Phase I Nivolumab + Relatlimab Nivolumab Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) Recruiting USA 0
NCT04676633 Phase I STP705 Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Recruiting USA 0
NCT04696055 Phase II Pembrolizumab + Regorafenib Pilot Study of Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors Recruiting USA 6
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04721132 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Not yet recruiting USA 0
NCT04740307 Phase II Lenvatinib + MK-1308A Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) Recruiting USA 3
NCT04770896 Phase III Atezolizumab + Lenvatinib Lenvatinib + Sorafenib Atezolizumab + Sorafenib A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251) Not yet recruiting CAN 19
NCT04777708 Phase I BO-112 + Pembrolizumab BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Not yet recruiting USA 0
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Not yet recruiting USA 0
NCT04823403 Phase I Ipilimumab + Nivolumab Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV) Recruiting 1
NCT04828486 Phase II Futibatinib + Pembrolizumab Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Not yet recruiting USA 0
NCT04829383 Phase II Atezolizumab + Bevacizumab A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7) Recruiting USA 0
NCT04857684 Phase I Atezolizumab + Bevacizumab SBRT + Atezolizumab + Bevacizumab in Resectable HCC Not yet recruiting USA 0
NCT04864054 Phase Ib/II ECT204 ECT204 T-Cell Therapy in Adults With Advanced HCC (ARYA3) Not yet recruiting USA 0